"It depends upon regulatory authorities, but I would guess that we would see the first people [getting the drug] towards the end of next year," said Professor Sir John Hardy (UCL Queen Square Institute of Neurology) on a breakthrough Alzheimer's treatment, lecanemab.
Close
